![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HMCN2 |
Gene summary for HMCN2 |
![]() |
Gene information | Species | Human | Gene symbol | HMCN2 | Gene ID | 256158 |
Gene name | hemicentin 2 | |
Gene Alias | HMCN2 | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256158 | HMCN2 | C30 | Human | Oral cavity | OSCC | 1.00e-02 | 1.84e-01 | 0.3055 |
256158 | HMCN2 | ATC13 | Human | Thyroid | ATC | 2.00e-43 | 9.70e-01 | 0.34 |
256158 | HMCN2 | ATC5 | Human | Thyroid | ATC | 9.09e-50 | 1.03e+00 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMCN2 | SNV | Missense_Mutation | rs761069612 | c.1838N>T | p.Thr613Ile | p.T613I | Q8NDA2 | protein_coding | deleterious(0.01) | possibly_damaging(0.743) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.15016N>T | p.Arg5006Cys | p.R5006C | Q8NDA2 | protein_coding | tolerated(0.09) | possibly_damaging(0.837) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.10891G>T | p.Asp3631Tyr | p.D3631Y | Q8NDA2 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HMCN2 | SNV | Missense_Mutation | novel | c.7705N>G | p.Leu2569Val | p.L2569V | Q8NDA2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HMCN2 | SNV | Missense_Mutation | novel | c.1740N>A | p.Asp580Glu | p.D580E | Q8NDA2 | protein_coding | deleterious(0.05) | probably_damaging(1) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HMCN2 | SNV | Missense_Mutation | novel | c.5950N>A | p.Pro1984Thr | p.P1984T | Q8NDA2 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.4747N>A | p.Gly1583Ser | p.G1583S | Q8NDA2 | protein_coding | tolerated(0.16) | possibly_damaging(0.762) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.11179N>A | p.Asp3727Asn | p.D3727N | Q8NDA2 | protein_coding | tolerated(0.17) | possibly_damaging(0.672) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
HMCN2 | SNV | Missense_Mutation | rs554164495 | c.11512N>A | p.Glu3838Lys | p.E3838K | Q8NDA2 | protein_coding | deleterious(0.03) | possibly_damaging(0.898) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HMCN2 | SNV | Missense_Mutation | rs555474617 | c.13429C>T | p.Arg4477Trp | p.R4477W | Q8NDA2 | protein_coding | deleterious(0) | benign(0.039) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |